HuiHe Healthcare Completes nearly 100 Million Yuan Financing

HuiHe Healthcare has recently completed a round of financing of nearly 100 million yuan. This round of financing was led by BioTrack Capital, followed by SDIC Capital, Guofang Capital and old shareholder Yuanhe Yuandian. Huaxing Capital served as the exclusive financial advisor for this financing. 

The funds raised will be used to continue to promote the continuous R&D, clinical approval of tricuspid interventional products, and other structural heart disease related products. Research and development of product pipeline.

HuiHe Healthcare is a high-tech company engaged in the R&D and production of structural heart disease interventional medical devices. It has China's first self-developed transvascular tricuspid valve interventional repair system. In addition, according to Yang Zhiwen, partner of Yuanhe Origin, the old shareholder, “While completing the tricuspid valve transvascular repair products, HuiHe Healthcare has also developed mitral valve regurgitation interventional products.”

The company's core product K-ClipTM (transcatheter tricuspid valve repair system) was developed for the disease of tricuspid regurgitation. Tricuspid regurgitation is mostly secondary to left heart (mitral or aortic valve) disease. It is a common structural heart disease. If the patient does not receive treatment in time, it will turn into heart failure. Once heart failure occurs, the patient will be within 5 years The mortality rate will exceed 50%. Therefore, how to ensure the smooth and safe treatment of tricuspid regurgitation and reduce the progressive development of severe tricuspid regurgitation with a mortality rate of up to 30% after the second thoracotomy has become a major issue.

At present, tricuspid regurgitation mainly relies on surgical thoracotomy, but this treatment method has problems such as difficulty in carrying out, high risk of surgery, and great harm to patients. Therefore, the interventional repair of tricuspid valve regurgitation has been recommended by the global guideline consensus. Companies on the structural heart disease track are developing and acquiring tricuspid valve interventional repair products. The K-Clip developed by HuiHe Healthcare is currently the fastest-growing product in China, and no competing products have entered the clinical stage.

Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on investing and incubating innovative life science companies in China. We are more than just capital providers. We invest in long-term partnerships with China’s leading healthcare entrepreneurs to build the next generation of world class companies.